Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) Assets Average (2016 - 2025)

Historic Assets Average for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to $123.5 million.

  • Aytu Biopharma's Assets Average rose 643.37% to $123.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $123.5 million, marking a year-over-year increase of 643.37%. This contributed to the annual value of $121.1 million for FY2025, which is 482.64% down from last year.
  • Latest data reveals that Aytu Biopharma reported Assets Average of $123.5 million as of Q4 2025, which was up 643.37% from $124.6 million recorded in Q3 2025.
  • Over the past 5 years, Aytu Biopharma's Assets Average peaked at $268.6 million during Q2 2021, and registered a low of $116.0 million during Q4 2024.
  • Moreover, its 5-year median value for Assets Average was $138.3 million (2023), whereas its average is $156.6 million.
  • In the last 5 years, Aytu Biopharma's Assets Average skyrocketed by 6750.1% in 2021 and then plummeted by 4295.7% in 2022.
  • Aytu Biopharma's Assets Average (Quarter) stood at $225.8 million in 2021, then crashed by 35.46% to $145.7 million in 2022, then dropped by 9.37% to $132.1 million in 2023, then decreased by 12.14% to $116.0 million in 2024, then increased by 6.43% to $123.5 million in 2025.
  • Its Assets Average stands at $123.5 million for Q4 2025, versus $124.6 million for Q3 2025 and $124.2 million for Q2 2025.